Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
Sponsor study identifier
interventional
390
6 countries
6
Study Start
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedPrimary objective: The primary objective of this trial is:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
September 9, 2005
Actual (reported)September 15, 2005
Actual (reported)Percentage of subjects achieving HbA1c < 7% at the end of the study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Sanofi-Aventis
Zagreb, Croatia
Sanofi-Aventis
Prague, Czechia
Sanofi-Aventis
Paris, France
Sanofi-Aventis
Bucharest, Romania
Sanofi-Aventis
Moscow, Russia
Sanofi-Aventis
Ljubljana, Slovenia
Valérie Pilorget, MD
Sanofi
First Submitted
September 9, 2005
First Posted
September 15, 2005
Study Start
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
January 11, 2011
Record last verified: 2011-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes
Contact the study team to confirm eligibility.